Randomized phase III trial comparing adjuvant S-1 to capecitabine in stage III colorectal cancer (JCOG0910, CRC Adj-CAPS)

ABSTRACT: Interventions: A: capecitabine. Patients in this group receive 8 courses of oral capecitabine, at a dose of 1,250 mg/m2 twice daily for 14 days every 21 days. B: S-1. Patients in this group receive 4 courses of oral S-1, at a dose of 40 mg/m2 twice daily for28 days every 42 days. Primary outcome(s): Disease-free survival Study Design: Parallel Randomized

DISEASE(S): Stage Iii Colorectal Cancer

PROVIDER: 2618731 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR